Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Edition
European
US
Oncology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Shared Insights on Treating BRAF
V600
-mutant Metastatic Cancers
September 2024
Shared Perspectives on Targeted Therapies for Metastatic BRAFV600 Mutations. Recorded live from Barcelona, Spain, during the 2024…
Read more
2nd June 2015
Genomic Marker Predicts Anti-PD-1 Response in Several Cancers
A phase II study identified the first genomic marker – mismatch repair (MMR) deficiency – to predict response to the anti-PD-1 antibody pembrolizumab…
2nd June 2015
Nivolumab Extends Survival for Patients With the Most Common Lung Cancer
Findings from a randomised phase III study indicate that PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small…
2nd June 2015
An introduction to ASCO 2015 by the 2014-15 president, Peter Paul Yu, MD, FACP, FASCO
Peter Paul Yu, MD, FACP, FASCO introduces ASCO 2015 and the conference themes – how to utilise data, to transform it into learning to impact patient care.
21st May 2015
PARP inhibitors and the EMBRACA study of talazoparib in BRCA-related metastatic breast cancer
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg…
21st May 2015
The mechanisms of BRCA-related breast cancer and molecular profiling
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany) and Prof…
21st May 2015
Current research into treatments for BRCA-related breast cancer and the phase 3 EMBRACA trial
Dr Kelly focuses on the phase 3 EMBRACA study, which is evaluating the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer.
21st May 2015
The role of BRCA and PARP in DNA repair and BRCA-related breast cancer
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg…
21st May 2015
The phase 3 EMBRACA study of talazoparib in BRCA-related metastatic breast cancer
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany) and Prof…
Loading posts...
« Previous
1
…
36
37
38
39
40
…
42
Next »